Clinical trial · Interventional
Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer
A Phase II, Open, Single-center Study of PD-1 Antibody and PARP Inhibitor as Consolidation Treatment for Patients With Extensive Stage Small Cell Lung Cancer Who Have Not Progressed After First-line Treatment
NCT04782089CI-TRIAL-00050470unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase II, Open, Single-center Study of Camrelizumab and Fluzoparib as Consolidation Treatment for Patients With Extensive stage small cell lung cancer Who Have Not Progressed after first-line treatment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Camrelizumab+Fluzoparib
- interventionNames
- Drug: Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors
Primary outcomes (1)
- measure
- Progression-free survival (PFS)
- timeFrame
- Approximately 3 years
- description
- To assess the efficacy of Camrelizumab and Fluzoparib combination therapy in terms of PFS
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. All subjects were required to sign the informed consent before starting the study; 2. Histologically documented Extensive stage small cell lung cancer； 3. ECOG PS 0\~1 ； 4. 18-75 years； 5. According to recist1.1, CR or PR was achieved after 4-6 cycles of first-line etoposide and platinum chemotherapy; 6. .Life expectancy ≥ 3 months； Exclusion Criteria: 1. Recurrence or distant metastasis of localized small cell lung cancer after chemotherapy or concurrent chemoradiotherapy； 2. Active infection including tuberculosis, HIV, hepatitis B and C； 3. Interstitial pneumonia (ILD), drug-induced pneumonia, radiation-induced pneumonia requiring steroid therapy or active pneumonia with clinical symptoms, or other moderate to severe lung diseases that seriously affect lung function; 4. Severe infection existed, including but not limited to infection complications, bacteremia, severe pneumonia, etc; 5. Symptomatic brain metastasis and cancerous meningitis;
References
Publications (0)
Data not yet available
No reference posted for this study.